Influence of the timing of low-dose aspirin on tolerability of prolonged-release nicotinic acid in patients at elevated cardiovascular risk

Current Medical Research and Opinion

Volumn 24, Issue 10, 2008, Pages 2815-2820

  Alves, J Delgado ^a   Steinhagen Thiessen, E ^b   Darioli, R ^c   Hostalek, Ulrike ^d   Vogt, A ^b  

^a HOSPITAL CURRY CABRAL   (Portugal)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c POLICLINIQUE MÉDICALE UNIVERSITAIRE   (Switzerland)

^d MERCK KGAA   (Germany)

Author keywords

Cardiovascular risk; HLD cholesterol; Lipid profiles; Prolonged release nicotinic acid; Tolerability

Indexed keywords

ACETYLSALICYLIC ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; NICOTINIC ACID;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVENING DOSAGE; FAMILY HISTORY; FEMALE; FLUSHING; GASTROINTESTINAL DISEASE; HUMAN; HYPERGLYCEMIA; INCIDENCE; LIPID BLOOD LEVEL; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; OUTCOMES RESEARCH; PHYSICIAN; RECOMMENDED DRUG DOSE; SIDE EFFECT; SKIN DISEASE; SUSTAINED DRUG RELEASE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTILIPEMIC AGENTS; ASPIRIN; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS, TYPE 2; FEMALE; FLUSHING; HUMANS; MALE; MIDDLE AGED; NIACIN; PLATELET AGGREGATION INHIBITORS; RISK FACTORS;

EID: 55549101606     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/03007990802381034     Document Type: Article

References (23)

1. Bruckert E, Baccara-Dinet M, McCoy F, et al. High prevalence of low HDL-cholesterol in a pan-European survey of 8545 dyslipidaemic patients. Curr Med Res Opin 2005;21:1927-34
2. Bruckert E, Baccara-Dinet M, Eschwege E. Low HDL-cholesterol is common in European Type 2 diabetic patients receiving treatment for dyslipidaemia: data from a pan-European survey. Diabet Med 2007;24:388-91
3. Wilson PW, Abbott RD, Castelli WP. High density lipoprotein cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis 1988;8:737-41
4. Gordon T, Castelli WP, Hjortland MC, et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977;62:707-14
5. Drexel H, Aczel S, Marte T, et al. Is atherosclerosis in diabetes and impaired fasting glucose driven by elevated LDL cholesterol or by decreased HDL cholesterol? Diabetes Care 2005;28:101-7
6. Goldbourt U, Yaari S, Medalie JH. Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men. Arterioscler Thromb Vasc Biol 1997;17:107-13
7. Kitamura A, Iso H, Naito Y, et al, High-density lipoprotein cholesterol and premature coronary heart disease in urban Japanese men. Circulation 1994;89:2533-9
8. Sharrett AR, Ballantyne CM, Coady SA. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2001;104:1108-13
9. Sacks FM. The relative role of low-density lipoprotein cholesterol and high-density lipoprotein cholesterol in coronary artery disease: evidence from large-scale statin and fibrate trials. Am J Cardiol 2001;88(Suppl):14-18N
10. Barter P, Gotto AM, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007;357:1301-10
11. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. Effect of atorvastatin on high density lipoprotein cholesterol and its relationship with coronary events: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Curr Med Res Opin 2004;20:627-37
12. Brown BG, Zhao X-Q, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583-92
13. Taylor AJ, Sullenberger LE, Lee HJ, et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004;110:3512-17
14. Taylor AJ, Lee HJ, Sullenberger LE. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr Med Res Opin 2006;22:2243-50
15. Gille A, Bodor ET, Ahmed K, et al. Nicotinic acid: pharmacological effects and mechanisms of action. Annu Rev Pharmacol Toxicol 2008;48:79-106
16. Vogt A, Kassner U, Hostalek U, et al. Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study. Vasc Health Risk Manag 2007;3:467-79
17. Guyton JR. Extended-release niacin for modifying the lipoprotein profile. Expert Opin Pharmacother 2004;5:1385-98
18. Dunn RT, Ford MA, Rindone JP, et al. Low-dose aspirin and ibuprofen reduce the cutaneous reactions following niacin administration. Am J Tber 1995;2:478-80
19. Jungnickel PW, Maloley PA, Vander Tuin EL, et al. Effect of two aspirin pretreatment regimens on niacin-induced cutaneous reactions. J Gen Intern Med 1997;12:591-6
20. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation 2002;105:310-15
21. Birjmohun RS, Kastelein JJ, Poldermans D, et al. Safety and tolerability of prolonged-release nicotinic acid in statin-treated patients. Curr Med Res Opin 2007;23:1707-13
22. Vogt A, Kassner U, Hostalek U, et al. Evaluation of the safety and tolerability of prolonged-release nicotinic acid in a usual care setting: the NAUTILUS study. Curr Med Res Opin 2006; 22:417-25
23. Dunn RT, Ford MA, Rindone JP, et al. Low-dose aspirin and ibuprofen reduce the cutaneous reactions following niacin administration. Am J Ther 1995;2:478-80